View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Bachem
18 July 2010

Ten New Products are Available from Bachem

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include atrial natriuretic factor (1-28) (human), the NPY Y4 receptor-selective agonist DL-2,7-Diaminosuberoyl-((Tyr32,Leu34)-Neuropeptide Y (32-36))2, Cyclo(-Arg-Gly-Asp-D-Phe-Cys) for conjugation to drugs, and immunology products for the detection of amylin, apelin, galanin-like peptide, monocyte chemotactic protein-1, pTH (1-34), splenopentin, and WE-14.

Today’s release of ten new products includes:

Atrial natriuretic peptides (ANP/ANF)

  • Atrial natriuretic factor (1-28) (human)

NPY Y4 receptor-selective agonist

  • DL-2,7-Diaminosuberoyl-((Tyr32,Leu34)-Neuropeptide Y (32-36))2

Cyclic RGD peptide with affinity for αvß3-integrins

  • Cyclo(-Arg-Gly-Asp-D-Phe-Cys)

Immunology products

  • Amylin (rat) – EIA kit (R – sr, pl), host: rabbit, extraction-free
  • Apelin-13 (human, bovine, mouse, rat) – EIA kit, host: rabbit, high sensitivity
  • Galanin-like peptide (GALP) (porcine) – EIA kit, host: rabbit, high sensitivity
  • Monocyte chemotactic protein-1 (MCP-1) (65-76) (human) – EIA kit, host: rabbit, high sensitivity
  • pTH (1-34) (rat) – EIA kit, host: rabbit, high sensitivity
  • Splenopentin – undiluted antiserum for immunohistochemistry, host: rabbit
  • WE-14 – EIA kit, host: rabbit, high sensitivity

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena